Focused Protein Profiling Strategies and Reverse-phase Arrays Drive Growth Multiplexed protein measurements using protein microarrays have several promising applications in drug discovery and clinical ...

Multi-center Phase I clinical study will evaluate the safety and tolerability of a monovalent strain of avian influenza A (H7N9) vaccine delivered intradermally by Vaxxas’ high-density microarray ...

Expression of CD24 and CD44 tumor cells in breast cancer patients who received neoadjuvant therapy. Background: Heat shock protein 27 (HSP27) is a stress-inducible protein preventing the accumulation ...

Vaxxas holds an exclusive license from The University of Texas at Austin (UTA) to the SARS-CoV-2 spike subunit vaccine (HexaPro) for vaccination using a patch. HexaPro, a second-generation SARS-CoV-2 ...

As protein arrays have become increasingly consistent and reliable, more scientists have begun to incorporate them into their proteomics experiments. Researchers are attracted by the technology’s ...

A phase I/II study of αGalactosylceramide-pulsed dendritic cells in patients with advanced or recurrent non-small cell lung cancer No significant financial relationships to disclose. This is an ASCO ...

As illustrated by Dr. Carl Borrebaeck, [4] of Lund University, Sweden, bioarrays may be based on proteins or on affinity reagents. Defined sets of proteins, such as autoantigens, are spotted on ...

Atlanta (June 16 2025)-- Emory University and Micron Biomedical today announced the first clinical trial of a novel rotavirus vaccine, CC24, delivered via dissolvable microarray technology, is now ...

The MarketWatch News Department was not involved in the creation of this content. -- Trial represents first-ever CDC-sponsored clinical trial of vaccine delivered via "patch" technology and utilizes ...